Skip to main content
Home

Breadcrumb

  1. Home
  2. News
  3. Search results
Displaying results 76 - 100 of 673 Clear search
Zyme Communications
The Cyclana Bio team	In vitro 3D model showing ECM components (green) and cells (magenta)
Healthcare and Life Science 19 May 2026

Cyclana Bio granted Health Research Authority approval and recruits first patients for clinical observational study in endometriosis

UK NHS grants HRA/REC approval for PEMP study with Peterborough and Cambridge hospitalsClinical observational study investigating underlying biology of endometriosis aims to uncover causal mechanisms and new druggable targets to improve treatment outcomes 
Zyme Communications
Jessica Payne, CCO, Qureight and Jeff Bornstein, Chief Medical Officer, Mediar Therapeutics
Healthcare and Life Science 13 May 2026

Qureight to support Mediar Therapeutics’ Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis

Qureight’s AI-powered quantitative imaging analytics platform and services to analyse HRCT images to evaluate changes in compartment-specific lung biomarkersThe focus of these efforts will be on the quantitative assessment of change from baseline in lung fibrosis
Zyme Communications
Enterprise Therapeutics
Healthcare and Life Science 12 May 2026

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

First investigational inhaled ENaC blocker to deliver clinically relevant and statistically significant change in lung function compared to placebo Inhaled therapeutic designed to treat the 10% of people with cystic fibrosis with the highest unmet medical need
Zyme Communications
Calla Lily Clinical Care’s Callavid platform for intravaginal drug delivery
Healthcare and Life Science 06 May 2026

Calla Lily Clinical Care doses first patients in clinical trial for intravaginal drug delivery platform for threatened miscarriage

FREEDOM study to evaluate progesterone delivery using Callavid intravaginal platformNIHR-funded trial in collaboration with University Hospitals Coventry and Warwickshire NHS Trust

London, UK, 06 May 2026: Calla Lily Clinical Care, a wo

Zyme Communications
 Brandon Pence, president and chief operations officer, FUJIFILM Biosciences	 Dr. Lindsay Davies, chief scientific officer, NextCell Pharma AB
Healthcare and Life Science 06 May 2026

FUJIFILM Biosciences and NextCell launch new commercial platform comprised of RUO Stromal Cells and Cell Culture Media

Collaboration results in platform to help researchers overcome challenges in MSC research

Zyme Communications
TrailBlazer StarBright Dye Label Kits
Healthcare and Life Science 05 May 2026

Bio-Rad expands range of TrailBlazer Kits for Antibody Conjugation to StarBright Dyes

Expanded Range Increases Access to Bio-Rad’s StarBright™ Dyes for Flow Cytometry and Western Blot Applications in Immunology Research

Zyme Communications
Dr Simon Walsh, Chief Scientific Officer, Qureight,
Healthcare and Life Science 05 May 2026

Qureight establishes Scientific Advisory Board focused on pulmonary hypertension

 

Zyme Communications
The Lab Thread Unified Lab Software Platform
Healthcare and Life Science 30 Apr 2026

Lab Thread introduces Unified Lab Software Platform to streamline biological research

Connects scientific teams, data and workflows within a single, fully integrated digital lab management system

Zyme Communications
Professor Dimitri Kullmann, Chief Scientific Officer of EpilepsyGTx
Healthcare and Life Science 29 Apr 2026

EpilepsyGTx appoints Professor Dimitri Kullmann as Chief Scientific Officer

Appointment of UCL Neurologist will accelerate the delivery of novel gene therapies for refractory epilepsy

Zyme Communications
Bio-Rad logo
Healthcare and Life Science 28 Apr 2026

Bio-Rad launches PTC Harmony 96 and PTC Harmony Deepwell Thermal Cyclers

New PTC Harmony Thermal Cycler Line Expands Access to Reliable, High-Performance PCR Across Academic and Biopharma Laboratories

Zyme Communications
Martin Stapleton, Chairman, PlaqueTec
Healthcare and Life Science 27 Apr 2026

PlaqueTec closes $5 million financing

Oversubscribed round backed by existing shareholders Investment will support development of cardiovascular disease database to be used to inform patient stratification and therapeutic development programmes

Cambridge, UK, 27 April 2026:

Zyme Communications
STORganoid™ ambient-temperature preservation solution for organoids and spheroids
Healthcare and Life Science 21 Apr 2026

Atelerix launches STORganoid cryo-free preservation solution for complex 3D cell models

Ambient-temperature preservation solution enables reliable storage and shipment of organoids and spheroids, to support growing adoption of New Approach Methodologies 

Zyme Communications
Atelerix
Healthcare and Life Science 15 Apr 2026

Atelerix forms strategic partnership with JH Health Ltd to expand non-cryogenic cell preservation capabilities in the Middle East

Agreement grants JH Health exclusive rights to use and distribute Atelerix’s portfolio of non-cryogenic preservation solutions in the regionExpands regional capabilities with funding for high-volume local manufacturing, as well as relevant regulatory filings and researc
Zyme Communications
bio-rad
Healthcare and Life Science 14 Apr 2026

Bio-Rad extends range of anti-idiotypic antibodies and anti-Fc mutation antibodies for bioanalysis and drug monitoring

Expanded antibody portfolio enhances detection of biologics and YTE-modified therapeutics for bioanalytical applications

Zyme Communications
BioUK logo
Healthcare and Life Science 14 Apr 2026

OBN rebrands to BioUK in alignment with its mission to catalyse success in UK life sciences

·        The new name reflects the national reach of the UK life science membership organisation and leverages its wide and long-established portfolio of Bio-prefixed events 

Zyme Communications
Transmission Electron microscopic image of Mpox virus particles Credit: CDC/ National Institute of Allergy and Infectious Diseases (NIAID)
Healthcare and Life Science 14 Apr 2026

ProImmune collaborates with The University of Texas Medical Branch to Advance Infectious Disease Research

Development of novel Ankyrons will enable study of emerging high-consequence infectious diseases to inform vaccines and treatments

Zyme Communications
Michael Lukesch, Founder and CEO at VALANX Biotech. Dr Klaus Orlinger, Chief Scientific Officer at VALANX Biotech.  Dr John Lambert, Chair of the Scientific Advisory Board at VALANX Biotech
Healthcare and Life Science 14 Apr 2026

VALANX Biotech establishes Scientific Advisory Board to advance ADC therapeutics

John Lambert, Morris Rosenberg and Peter de Waele appointed as Chair and members of the SAB respectivelySAB provides scientific expertise and drug development experience, supporting advancement of the Company’s GoldenSite™ conjugation platform and its LIV-1 targeting le
Zyme Communications
SPT Labtech’s firefly®+ in use at EMBL GeneCore
Healthcare and Life Science 13 Apr 2026

SPT Labtech and EMBL GeneCore collaborate to advance fully walkaway automation in genomics workflows

firefly+ liquid handling platform installed at EMBL GeneCoreCollaboration to enable more streamlined end-to-end workflows while maintaining sample integrity

Cambridge, UK, and Heidelberg, Germany, 13 April 2026: SPT Labtech, a global le

Zyme Communications
FairJourney Bio
Healthcare and Life Science 13 Apr 2026

FairJourney Bio opens Cryo-EM structural biology facility in San Diego

Antibody discovery expert expands presence in US biotech ecosystem with world-leading atomic-resolution structural biology capabilities

 

Zyme Communications
Carterra
Healthcare and Life Science 09 Apr 2026

William Blair analysts name Carterra a winner in life science tools for enabling AI drug discovery at unprecedented scale

Carterra, with its HT-SPR technology platforms, is listed alongside large public companies as a technology provider to capitalize on the likely growth in wet lab work driven by the increasing use of AI in early discovery

Zyme Communications
Virica Biotech
Healthcare and Life Science 09 Apr 2026

Virica Biotech and FUJIFILM Biosciences Collaborate Under the Canada–Japan Co-Innovation Program to Advance AAV Production Enhancers

Efficient production of Adeno-Associated Virus (AAV) vectors at scale for in vivo gene therapies remains a key bottleneck for broad patient access and sustainable manufacturing costs 

Zyme Communications
Sapna Vyas, Head of Scientific Programs at Axol Bioscience
Healthcare and Life Science 31 Mar 2026

PRISM ALS: New stem cell models could transform research into treatments for MND/ALS

PRISM ALS is a new global initiative designed to accelerate the discovery of effective treatments for ALS/MND by improving access to specially grown, patient-derived stem cell models that better reflect the biological diversity of the disease. The collaboration brings t
Zyme Communications
Broken String Biosciences Rebrands
Healthcare and Life Science 31 Mar 2026

Broken String Biosciences rebrands to reflect strategic evolution as demand grows for unbiased genome-wide off-target analysis

Rebrand follows appointment of new leadership as company drives commercialization of INDUCE-seq platform to address regulatory gaps in off-target reporting for gene editing programs

Zyme Communications
iXCells Biotechnologies
Healthcare and Life Science 24 Mar 2026

iXCells Biotechnologies Joins International Collaboration to Evaluate Chemotherapeutic Toxicity in Human Organoids

Joint initiative with Rosebud Biosciences, Kantify, and funded by Incite will identify and quantify off-target toxicities in chemotherapy patientsDevelopment of patient-specific human organoids models for heart, liver, and kidney tissues

San Die

Zyme Communications
An example of the visual output provided by the new QuanSA PyMOL plugin. m32 is approximately 50 times more potent than the structurally similar m01, despite having near identical patterns of hydrogen bonding (red and blue cones). The difference is explained by additional steric contributions indicated by the surface patches highlighted by the black arrows.
Healthcare and Life Science 24 Mar 2026

Optibrium Introduces Graphical Interface for QuanSA to Enhance Ligand-Based Affinity Predictions

New user interface provides visual insights to guide compound optimisation

Pagination

  • First page «
  • Previous page ‹
  • …
  • Page 2
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • …
  • Next page ›
  • Last page »
Receive our newsletter

Cambridge Network Limited is a company registered in England under company No. 3400152

The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

Email: [email protected], Tel: 01223 746801

© 2026 Cambridge Network. All Rights Reserved.

Website by KISS